Summary by Moomoo AI
AMIE VACCINES CO., LTD. (“AMY VACCINES”) ANNOUNCED ON MARCH 2, 2024 THAT A PHASE II CLINICAL TRIAL OF ITS FOUR-PRICE COMBINED CEREBRAL INFLUENZA VACCINE HAS BEEN OFFICIALLY LAUNCHED AT THE YUNNAN CENTER FOR DISEASE PREVENTION CONTROL. The trial was conducted by Baoshan Longyang District Disease Prevention Control Center and Dali State Weishan Yi Hui Autonomous County Disease Prevention Control Center as a research site. EPIDEMIC MENINGITIS IS AN ACUTE INFECTIOUS DISEASE CAUSED BY THE NETHER MENINGITIS COCCUS. THE QUADRUPLE COMBINATION VACCINE DEVELOPED BY EMERY IS DESIGNED TO PREVENT THE VIRUS FROM GROUP A, GROUP C, GROUP Y AND GROUP W135. The company has completed the construction of the relevant vaccine production workshop and expects that the product will reach a wide market once the product is launched. WITH GLOBAL MENINGITIS COMBINED VACCINE SALES OF US$14.18 BILLION IN 2023, EMERY'S NEW PRODUCTS WILL HELP CONTROL ENCEPHALOPAEMIA IN CHINA. Mr. Zhou Yan, Chairman of the Board, Executive Director and Chief Executive Officer, issued this announcement on March 4, 2024.